STAAR Surgical (STAA) Doubles On FDA 510(k) Clearance
More News related to STAA
- STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
- STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
- STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
- STAAR Surgical Collamer(R) Accommodating Study Team Reports First Phase Assessments at AAO
- STAAR Surgical (STAA) Reports Progress on Japanese Application for Approval of Visian Implantable Collamer Lens
More News related to FDA
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
STAAR Surgical Company (Nasdaq: STAA) has doubled after the company announced that the FDA has granted 510(k) clearance for its Epiphany Injector System for use with the Affinity Collamer Three-Piece NTIOL and the Elastimide Silicone NTIOL.
Introduction of the Epiphany will usher in a new era of insertion devices for the company and pave the way for the future introduction of a preloaded injector for the U.S. market.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
